See more : Astoria Investments Ltd (ARA.JO) Income Statement Analysis – Financial Results
Complete financial analysis of Awakn Life Sciences Corp. (AWKNF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Awakn Life Sciences Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- B&G Foods, Inc. (BGS) Income Statement Analysis – Financial Results
- The Brooker Group Public Company Limited (BTC.BK) Income Statement Analysis – Financial Results
- ABO-Group Environment NV (ABO.BR) Income Statement Analysis – Financial Results
- Vision Energy Corp (VENG) Income Statement Analysis – Financial Results
- Floyd Public Company Limited (FLOYD.BK) Income Statement Analysis – Financial Results
Awakn Life Sciences Corp. (AWKNF)
About Awakn Life Sciences Corp.
Awakn Life Sciences Corp., a biotechnology company, engages in the researching, developing, operations, and delivering of psychedelic therapeutics to treat addiction and other mental health conditions in the United Kingdom and Europe. The company is headquartered in Toronto, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 87.37K | 1.50M | 236.04K | 0.00 |
| Cost of Revenue | 18.30K | 603.53K | 512.87K | 0.00 |
| Gross Profit | 69.08K | 891.81K | -276.83K | 0.00 |
| Gross Profit Ratio | 79.06% | 59.64% | -117.28% | 0.00% |
| Research & Development | 827.82K | 1.57M | 3.31M | 0.00 |
| General & Administrative | 2.73M | 4.06M | 4.40M | 666.73K |
| Selling & Marketing | 439.59K | 1.40M | 1.63M | 103.18K |
| SG&A | 3.17M | 8.51M | 6.54M | 823.07K |
| Other Expenses | 0.00 | -2.37K | 10.35K | 0.00 |
| Operating Expenses | 87.37K | 10.08M | 9.85M | 1.46M |
| Cost & Expenses | 4.00M | 10.69M | 10.03M | 1.46M |
| Interest Income | 87.67K | 305.79K | 0.00 | 13.10K |
| Interest Expense | 0.00 | 266.52K | 205.43K | 0.00 |
| Depreciation & Amortization | 18.30K | 14.41K | 181.41K | 84.00 |
| EBITDA | -3.91M | -5.26M | -16.08M | -840.22K |
| EBITDA Ratio | -4,473.00% | -574.33% | -4,072.48% | 0.00% |
| Operating Income | -3.93M | -9.19M | -9.79M | -840.30K |
| Operating Income Ratio | -4,493.94% | -614.69% | -4,149.34% | 0.00% |
| Total Other Income/Expenses | 255.42K | 306.31K | -6.86M | -652.12K |
| Income Before Tax | -3.67M | -9.65M | -16.47M | -1.48M |
| Income Before Tax Ratio | -4,201.61% | -645.44% | -6,978.45% | 0.00% |
| Income Tax Expense | 0.00 | -509.02K | -525.87K | -215.30K |
| Net Income | -5.10M | -9.14M | -15.95M | -1.26M |
| Net Income Ratio | -5,840.14% | -611.40% | -6,755.65% | 0.00% |
| EPS | -0.09 | -0.36 | -0.73 | -0.10 |
| EPS Diluted | -0.13 | -0.36 | -0.73 | -0.10 |
| Weighted Avg Shares Out | 39.68M | 25.20M | 21.96M | 12.63M |
| Weighted Avg Shares Out (Dil) | 29.07M | 25.20M | 21.96M | 12.63M |
Awakn Life Sciences announces licensing deal for oral ketamine formulation
Awakn Life Sciences Corp (NEO:AWKN) announced that it has signed a global licensing agreement with private pharmaceutical technology firm LTS Lohmann Therapie-Systeme AG for its proprietary S-ketamine formulation. The biotechnology company said it would have exclusive use of LTS' proprietary S-ketamine formulation, administered...
Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS
Agreement Includes Exclusive Rights for Treatment of Addiction, Anxiety and Eating Disorders Also Includes Access to Phase 1 Data and Patents Filed in US and Key International Markets Toronto, Ontario--(Newsfile Corp. - December 20, 2023) - Awakn Life Sciences Corp....
Awakn Life Sciences Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - December 15, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), shares a corporate update...
Awakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001
AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use Disorder Toronto, Ontario--(Newsfile Corp. - November 15, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a clinical-stage...
Awakn Life Sciences Announces Receipt of Notice of Non-Compliance with Cboe Exchange Continued Listing Requirements
Toronto, Ontario--(Newsfile Corp. - November 10, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today that...
Awakn Life Sciences Engages Orphan Insight Ltd. to Advance Market Access, Pricing, and Reimbursement Strategies for AWKN-P001 Targeting Severe Alcohol Use Disorder
Toronto, Ontario--(Newsfile Corp. - October 31, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces it has...
Awakn Life Sciences Completes MDMA Zydis(R) ODT Feasibility Study
Study Confirms MDMA Is Stable on Zydis(R) ODT and Suitable for Pre-Gastric Absorption Toronto, Ontario--(Newsfile Corp. - October 4, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical stage biotechnology company developing therapeutics to...
Awakn Life Sciences Provides Corporate Update
Announces Closing of Third Tranche of Private Placement Toronto, Ontario--(Newsfile Corp. - September 14, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus...
Awakn Life Sciences Submits Clinical Trial Application for Phase III Trial of AWKN-P001
AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use Disorder Toronto, Ontario--(Newsfile Corp. - September 6, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a...
Awakn Life Sciences Completes Sale of Awakn Clinics In Norway
Sale Completes Awakn's Exit From Healthcare Services To Focus Solely on Biotechnology Research and Development Toronto, Ontario--(Newsfile Corp. - August 1, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology...
Source: https://incomestatements.info
Category: Stock Reports